The American Journal of Managed Care

Promising Clinical Trial Updates in IPF/PPF

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU

Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive ...

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary ...
The American Journal of Managed Care

Beyond the Data: Evidence-Based Decision-Making in IPF and PPF Management

Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside ...
Pulmonology Advisor

Study Finds No Link Between PCSK6 and Worse Respiratory Outcomes in Mixed Fibrotic ILD

The levels of PCSK6 are not associated with worse respiratory outcomes in patients with mixed fibrotic interstitial lung disease.
Medscape

EMA OKs New Option for Pulmonary Fibrosis

The oral therapy is intended for adults with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis, two fibrotic ...
FOX8 Cleveland

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential ...
Pharmabiz

EMA committee recommends marketing approval for Boehringer Ingelheim’s Jascayd to treat IPF and progressive pulmonary fibrosis

EMA committee recommends marketing approval for Boehringer Ingelheim’s Jascayd to treat IPF and progressive pulmonary fibrosis: Ingelheim, Germany Monday, May 25, 2026, 10:00 Hr ...
Nasdaq

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Further, open label extension data published in 2023 showed ...
Pharmabiz

Boehringer Ingelheim’s Jascayd approved in Japan to treat idiopathic pulmonary fibrosis & progressive pulmonary fibrosis

Boehringer Ingelheim’s Jascayd approved in Japan to treat idiopathic pulmonary fibrosis & progressive pulmonary fibrosis: Ingelheim, Germany Tuesday, May 19, 2026, 13:00 Hrs [IS ...
Yahoo Finance

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

JASCAYD ® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the ...